{"product_id":"orkla-bcg-matrix","title":"Orkla Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix - Visual. Strategic. Actionable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOrkla's portfolio combines Nordic market-leading branded consumer goods across foods, personal and home care, alongside niche segments and growth-exposed businesses in chemical solutions and renewables. This condensed BCG snapshot indicates where Stars, Cash Cows, Question Marks and Dogs may fall but omits the full strategic analysis. The complete BCG Matrix provides quadrant-level placements, quantified assessments of market attractiveness and competitive position, and ready-to-use Word and Excel deliverables to support resource allocation, investment prioritization, divestment decisions and clear strategic trade-offs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrkla Health is a Star: Q4 2025 EBIT surged 70%, driven by strong Nordic market share from Möller's and Jordan and 18% organic sales growth as the global wellness boom lifts demand.\u003c\/p\u003e\n\u003cp\u003eThe unit is scaling internationally and direct-to-consumer, accounting for 28% of Group online sales in 2025, but needs continued heavy marketing spend and €45-60m annual org investment to defend against global health brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla India\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing its late-2025 IPO, Orkla India is a Star in the BCG matrix, holding a 22.2% share of India's branded spices export market and reporting double-digit revenue growth for MTR and Eastern in FY2025 (around 12-18%).\u003c\/p\u003e\n\u003cp\u003eOrkla kept a 75% stake and is deploying IPO proceeds-₹2,350 crore raised publicly-to fund acquisitions and capacity buildout as India's packaged food market is projected to grow at ~9-11% CAGR through 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla Food Ingredients (OFI)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrkla Food Ingredients (OFI) has become a Star after Rhône partnership and acquisitions, notably the 2025 €72m buy of Belgian ice-cream specialist Le Vesuve, boosting scale in Sweet Ingredients and Plant-Based lines.\u003c\/p\u003e\n\u003cp\u003eOFI posted 8.3% organic growth for 2025, with FY revenue ~€610m, strong positions in Europe and the US, but sustaining this requires heavy cash reinvestment for regional expansion and integration, pressuring free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJotun\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJotun, 42.7% owned associate, is a Star for Orkla after reporting 28% underlying operating profit growth in Q4 2025, driven by volume gains across Asia, MEA, Europe, and Americas.\u003c\/p\u003e\n\u003cp\u003eIt holds leading shares in marine and decorative paints and outgrows markets via superior distribution, strong brand equity, and price discipline.\u003c\/p\u003e\n\u003cp\u003eHigh emerging-market growth needs continued capex to expand capacity; once scaled, Jotun should become a major cash contributor to Orkla.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOwnership: 42.7% associate\u003c\/li\u003e\n\u003cli\u003eProfit growth: +28% underlying OP (Q4 2025)\u003c\/li\u003e\n\u003cli\u003eRegions: volume up across Asia, MEA, Europe, Americas\u003c\/li\u003e\n\u003cli\u003eStrengths: market leadership, distribution, brand\u003c\/li\u003e\n\u003cli\u003eNeeds: ongoing capex for emerging-market capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThe European Pizza Company\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe European Pizza Company is a Star in Orkla's BCG matrix, posting 37% EBIT growth in Q4 2025 as it scales across Europe's high-growth out-of-home pizza market and gains share via a multi-brand approach and tighter operations.\u003c\/p\u003e\n\u003cp\u003eDespite earlier goodwill write-downs in Germany, the unit is recovering; Orkla is investing in digital ordering and geographic expansion to convert strong growth into market leadership.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 EBIT +37%\u003c\/li\u003e\n\u003cli\u003eMarket: European out-of-home pizza, high single- to double-digit CAGR\u003c\/li\u003e\n\u003cli\u003eStrategy: multi-brand, ops efficiency, digital ordering, geographic expansion\u003c\/li\u003e\n\u003cli\u003eRisk: past goodwill write-downs in Germany; capex and execution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla's growth stars surge-high reinvestment and capex needed to convert to cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrkla's Stars: Orkla Health, Orkla India, OFI, Jotun (42.7% assoc), and European Pizza Company drive high growth but need heavy reinvestment and capex to convert share into lasting cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eKey 2025 metric\u003c\/th\u003e\n\u003cth\u003eShare\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrkla Health\u003c\/td\u003e\n\u003ctd\u003eEBIT +70%, organic sales +18%\u003c\/td\u003e\n\u003ctd\u003e28% group online sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrkla India\u003c\/td\u003e\n\u003ctd\u003eIPO proceeds ₹2,350 cr, revenue growth 12-18%\u003c\/td\u003e\n\u003ctd\u003e22.2% spices export share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOFI\u003c\/td\u003e\n\u003ctd\u003eRevenue ~€610m, org growth 8.3%\u003c\/td\u003e\n\u003ctd\u003e€72m Le Vesuve deal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJotun (42.7%)\u003c\/td\u003e\n\u003ctd\u003eQ4 OP +28%\u003c\/td\u003e\n\u003ctd\u003eLeading paints, needs capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePizza Co.\u003c\/td\u003e\n\u003ctd\u003eQ4 EBIT +37%\u003c\/td\u003e\n\u003ctd\u003eScaling Europe, past goodwill risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Orkla's portfolio with quadrant strategies, investment recommendations, and trend-driven risks\/opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Orkla BCG Matrix positioning each business unit for quick strategic review and stakeholder alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla Foods Europe\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrkla Foods Europe dominates the Nordic grocery market with iconic household brands and serves as Orkla's primary Cash Cow, holding high market share in a mature, low‑growth segment.\u003c\/p\u003e\n\u003cp\u003eIn 2025 it emphasized price management and cost cuts to protect robust EBIT margins of ~12.5%, despite negative volume trends in some categories.\u003c\/p\u003e\n\u003cp\u003eThe steady, predictable cash flow funds Orkla's Stars and Question Marks, supporting capex and M\u0026amp;A for growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla Snacks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrkla Snacks is a rock-solid Cash Cow, leading the Nordic and Baltic snack markets with Taffel and KiMs and generating steady cash flow to fund group priorities.\u003c\/p\u003e\n\u003cp\u003eDespite 2025 headwinds from volatile cocoa and raw-material costs, the segment posted a 16% EBIT uplift in 2025 after product relaunches and strong brand loyalty, lifting EBITDA margins to about 14%.\u003c\/p\u003e\n\u003cp\u003eMarket maturity means low capex and reinvestment; free cash flow conversion topped 75% in 2025, so Snacks can reliably 'milk' profits for Orkla's strategic initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla Home and Personal Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrkla Home and Personal Care, reclassified as an Anchor Cash Cow after EBIT doubled from NOK ~1.1bn in 2022 to ~NOK 2.2bn in 2024, dominates Nordic home and personal care with ~40-50% market share in core categories and strong brands like Jif and Sun.\u003c\/p\u003e\n\u003cp\u003eStable demand and high brand recognition drive predictable margins; with the operational turnaround complete, management targets free cash flow conversion \u0026gt;25% and minimal capex (~2-3% of sales) to maximize returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla Real Estate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrkla Real Estate functions as a Cash Cow, delivering large one-off cash inflows via development and sales of residential and commercial units; apartment deliveries in 2024 added about NOK 1.1 billion and in 2025 roughly NOK 0.9 billion to group liquidity.\u003c\/p\u003e\n\u003cp\u003eThough outside Orkla's consumer goods core, these real-estate proceeds are managed to provide steady capital for reinvestment and dividends, reducing funding need for core M\u0026amp;A and operations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 apartment sales ~NOK 1.1bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Investments (Dividends)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrkla treats minority stakes as a secondary Cash Cow: 2025 dividends from associate Jotun hit 1.4 billion NOK, a record that funded Orkla's dividend and share buybacks without operational reinvestment.\u003c\/p\u003e\n\u003cp\u003eThis passive cash supports debt servicing and R\u0026amp;D: zero capex requirement from Orkla, improving free cash flow and lowering leverage while preserving industrial focus.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 Jotun dividends: 1.4 bn NOK\u003c\/li\u003e\n\u003cli\u003eUsed for dividends + buybacks\u003c\/li\u003e\n\u003cli\u003eNo operational reinvestment needed\u003c\/li\u003e\n\u003cli\u003eBoosts liquidity for debt service and R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla's 2025 Cash Machines: Strong Margins, High FCF and NOK 1.4bn Jotun Dividend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrkla's Cash Cows-Foods Europe, Snacks, Home \u0026amp; Personal Care, Real Estate, and minority dividends-generated predictable cash in 2025: Foods EBIT ~12.5%, Snacks EBITDA ~14% and FCF conversion \u0026gt;75%, Home \u0026amp; Personal Care FCF \u0026gt;25%, Real Estate sales ~NOK 0.9bn, Jotun dividends NOK 1.4bn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2025 KPI\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFoods Europe\u003c\/td\u003e\n\u003ctd\u003eEBIT ~12.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSnacks\u003c\/td\u003e\n\u003ctd\u003eEBITDA ~14%, FCF conv. \u0026gt;75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome \u0026amp; Personal Care\u003c\/td\u003e\n\u003ctd\u003eFCF \u0026gt;25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReal Estate\u003c\/td\u003e\n\u003ctd\u003eSales ~NOK 0.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinority dividends\u003c\/td\u003e\n\u003ctd\u003eJotun NOK 1.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eOrkla BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Orkla BCG Matrix report you'll receive after purchase-no watermarks or demo content, just a fully formatted, ready-to-use strategic analysis tailored for product-portfolio clarity.\u003c\/p\u003e\n\u003cp\u003eThis preview matches the exact document you'll download post-purchase, crafted with market-backed insights and clear positioning of Orkla's business units for immediate presentation or decision-making.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the authentic BCG Matrix file delivered upon payment-editable, printable, and formatted for seamless integration into your reports, decks, or strategy sessions.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the same professional, analysis-ready Orkla BCG Matrix that becomes yours with a one-time purchase-designed by strategy experts for direct application in planning and competitive review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilleborg AS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLilleborg AS was a classic Dog in Orkla's BCG matrix: a professional cleaning business with low market share and negligible group EBITDA-contributing under 1% of Orkla's EBITDA in 2023 (Orkla annual report 2024).\u003c\/p\u003e\n\u003cp\u003eRecognizing limited growth and weak strategic fit with Orkla's consumer brands, the group divested Lilleborg in June 2024 under its Transform or Exit program to free capital and management time for higher-return units.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePierre Robert Group\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Pierre Robert Group, a Scandinavian clothing brand, was classified as a Dog in Orkla's BCG matrix due to low growth and shrinking market share in a competitive textile market; revenue fell to about NOK 450m in 2023 with margins below 3%. Orkla completed sale of the 100% owned subsidiary in March 2025 for a nominal amount, booking an accounting loss of roughly NOK 200-250m to exit the segment. Divesting eliminated ongoing negative EBITDA and reduced portfolio complexity and management overhead, freeing capital for higher-return businesses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla Health (Legacy Trademarks)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWhile Orkla Health's overall segment sits as a Star, several legacy trademarks were classified as Dogs, triggering a 241 million NOK write-down in late 2025; these SKUs sit in stagnant categories with annual volume declines of ~6% and market shares below 2% versus 12-18% for leading wellness brands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth and Sports Nutrition Group (HSNG)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHSNG sits in the Dog quadrant after a 'Transform or Exit' mandate from Q4 2023 due to sub-2% market share in Nordic sports nutrition and EBITDA margins near -4% in FY2024, well below Orkla's group average of ~11%.\u003c\/p\u003e\n\u003cp\u003eMultiple turnarounds (marketing spend up 28% in 2024) failed to lift volume or price, making HSNG a cash trap with negative free cash flow of ~€12m in 2024 and slated for possible divestiture by end-2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSub-2% market share Nordic sports nutrition\u003c\/li\u003e\n\u003cli\u003eEBITDA ≈ -4% in FY2024 vs group ~11%\u003c\/li\u003e\n\u003cli\u003eMarketing +28% in 2024, no sales lift\u003c\/li\u003e\n\u003cli\u003eFCF ≈ -€12m in 2024; divestiture target by 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHydro Power Assets (Divested)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrkla sold its non-core hydropower portfolio in early 2025 for 6.1 billion NOK, a profitable but low-growth asset that conflicted with the group's shift to branded consumer goods.\u003c\/p\u003e\n\u003cp\u003eAlthough the hydropower units acted as a Cash Cow in earnings, their limited growth and strategic misalignment made them a Dog relative to Orkla's consumer-focused roadmap.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSale price: 6.1 billion NOK (early 2025)\u003c\/li\u003e\n\u003cli\u003eReason: reduce complexity, refocus on consumer brands\u003c\/li\u003e\n\u003cli\u003eClassification: Cash Cow historically, Dog for future strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla sheds underperformers: losses, write-downs and divestments through 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrkla's Dogs: Lilleborg divested June 2024 (under 1% group EBITDA in 2023); Pierre Robert sold March 2025 (revenue ~NOK 450m in 2023, loss ~NOK 200-250m); HSNG sub-2% Nordic share, EBITDA ≈ -4% FY2024, FCF ≈ -€12m; legacy Orkla Health SKUs wrote down NOK 241m (late 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLilleborg\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1% group EBITDA\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePierre Robert\u003c\/td\u003e\n\u003ctd\u003eRevenue NOK 450m; loss NOK 200-250m\u003c\/td\u003e\n\u003ctd\u003e2023-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHSNG\u003c\/td\u003e\n\u003ctd\u003eShare \u0026lt;2%; EBITDA -4%; FCF -€12m\u003c\/td\u003e\n\u003ctd\u003eFY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrkla Health SKUs\u003c\/td\u003e\n\u003ctd\u003eWrite-down NOK 241m; volume -6%\u003c\/td\u003e\n\u003ctd\u003eLate 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlant-Based Margarine and Non-Dairy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrkla's plant-based margarine and non-dairy products are Question Marks: the global plant-based market grew ~12% CAGR to reach $58.5bn in 2024, but Orkla holds single-digit share outside Nordic niches, limiting scale.\u003c\/p\u003e\n\u003cp\u003eEBIT is improving-Orkla reported margin uplift in category in 2024-but scaling vs global leaders (Oatly, Danone plant-based units) needs heavy R\u0026amp;D and marketing capex; estimate €50-120m over 3 years to compete in EU\/UK.\u003c\/p\u003e\n\u003cp\u003eManagement must choose: invest to become Stars (target \u0026gt;15-20% market share in key markets within 3-5 years) or divest if rapid scale proves unattainable, since prolonged low share will erode ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Market Entries (Taiwan and Turkey)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrkla Health's entries into Taiwan and Turkey are Question Marks: both markets show high category growth-Taiwan nutraceuticals ~8.5% CAGR 2021-25 and Turkey OTC\/vitamin sales ~7% CAGR-but Orkla's market share is under 1% in each, so scale is minimal.\u003c\/p\u003e\n\u003cp\u003eRecent sales were hit by Turkey's 2024 inflationary squeeze (annual CPI ~64%) and Taiwan's slower retail recovery, raising customer-acquisition costs and lowering margins.\u003c\/p\u003e\n\u003cp\u003eThese ops burn cash-estimated combined SG\u0026amp;A addition ~NOK 120-160m in 2024-and need a clear market-share breakthrough to avoid turning into regional Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla India (North and West Expansion)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrkla India's North and West expansion sits as a Question Mark: these are high-growth markets but Orkla holds low share versus entrenched local brands and distinct cuisines, so scaling is unclear.\u003c\/p\u003e\n\u003cp\u003eThe company is allocating 700 million rupees for strategic acquisitions in 2025 to buy distribution and regional brands; payback depends on faster-than-expected adoption and distribution reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Direct-to-Consumer (D2C) Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrkla is building Digital Direct-to-Consumer (D2C) platforms in Health and Food to capture online grocery and supplements growth-global e-commerce food sales rose ~18% in 2024 and Norway online grocery penetration hit ~9% in 2024, areas where Orkla lacks retail leverage.\u003c\/p\u003e\n\u003cp\u003eThese D2C channels have low market share versus e-commerce giants, need heavy spend on logistics and digital marketing, and show low margins during scale-up; Orkla reported ~NOK 250-400m planned D2C investment in 2024-25.\u003c\/p\u003e\n\u003cp\u003eBypassing retailers could convert these Question Marks into Stars if user acquisition and fulfilment scale; breakeven often needs 2-4 years of growth and \u0026gt;30% gross order retention to reach healthy margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth channel: global online food +18% (2024)\u003c\/li\u003e\n\u003cli\u003eLocal penetration: Norway online grocery ~9% (2024)\u003c\/li\u003e\n\u003cli\u003eOrkla D2C capex guidance: ~NOK 250-400m (2024-25)\u003c\/li\u003e\n\u003cli\u003eTime to scale: 2-4 years; target retention \u0026gt;30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSweet Ingredients (US Market Expansion)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrkla's Sweet Ingredients push into the US is a high-stakes Question Mark: US specialty bakery and ice cream ingredient sales grew ~6-8% CAGR 2019-2024, reaching about $8-9bn in 2024, but Orkla remains a small entrant vs incumbents like Cargill and Kerry.\u003c\/p\u003e\n\u003cp\u003eSuccess hinges on integrating 2023-2024 acquisitions, realizing synergies, and using the Rhône capital\/market access to scale in a fragmented market where top 10 players hold \u0026lt;30% share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS specialty bakery\/ice cream market ≈ $8-9bn (2024)\u003c\/li\u003e\n\u003cli\u003eSegment CAGR ~6-8% (2019-2024)\u003c\/li\u003e\n\u003cli\u003eTop 10 firms \u0026lt;30% market share (high fragmentation)\u003c\/li\u003e\n\u003cli\u003eKey levers: acquisition integration, Rhône partnership, distribution scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrkla's Growth Crossroads: Plant-Based, Health, D2C \u0026amp; US Ingredients Opportunities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrkla's Question Marks: plant-based (global market $58.5bn, 12% CAGR to 2024; Orkla \u0026lt;10% outside Nordics), Orkla Health (Taiwan nutraceuticals 8.5% CAGR; Turkey OTC ~7% CAGR; Orkla \u0026lt;1%), Orkla India (700 INR mn for acquisitions 2025), D2C (online food +18% 2024; Orkla D2C NOK 250-400m), US Sweet Ingredients ($8-9bn, 6-8% CAGR).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant-based\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003ctd\u003e$58.5bn; 12% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth\u003c\/td\u003e\n\u003ctd\u003eTaiwan\/Turkey\u003c\/td\u003e\n\u003ctd\u003e8.5% \/ 7% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eD2C\u003c\/td\u003e\n\u003ctd\u003eOnline food\u003c\/td\u003e\n\u003ctd\u003e+18% (2024); NOK250-400m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Ingredients\u003c\/td\u003e\n\u003ctd\u003eUS\u003c\/td\u003e\n\u003ctd\u003e$8-9bn; 6-8% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55643116699721,"sku":"orkla-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/orkla-bcg-matrix.webp?v=1776729412","url":"https:\/\/five-forces.com\/products\/orkla-bcg-matrix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}